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Abstract. Aim: A prospective study for stage IIIA-B non-
small cell lung cancer (NSCLC), with three-times daily (3td)
radiotherapy (RT), after induction chemotherapy (iCT), with
or without surgery. Patients and Methods: Induction cisplatin
and gemcitabine chemotherapy was delivered. Surgery and
postoperative (post-op) radiotherapy were planned for
responsive stage IIIA patients; definitive irradiation was
performed in unresectable IIIA and IIIB patients. Doses of
54.4 and 64.6 Gy were delivered for the post-op and definitive
treatments, respectively. Results: Out of 52 patients (pts), 37
received 3tdRT as definitive (18 pts) or post-op treatment (19
pts). Overall, the failures were similar between post-op and
definitive 3tdRT (78.9% vs. 77.8% ). In the post-op treatment,
metastases and local failures were 52.6% and 10.5% ,
respectively and in the definitive radiotherapy, the incidence
was similar (local 33.3% vs. systemic 44.4% ). The five-year
overall survival (OS) was 25% for the post-op and 21% for
the definitive patients (p=0.87). Conclusion: Three-times daily
postoperative radiotherapy did not improve the outcome in
NSCLC, but for unresectable patients, this approach may have
a role in selected cases.
For locally advanced non-small cell lung cancer (NSCLC),
the high rate of metastasis requires chemotherapy (CT)
integration with local treatments, especially in cases of
mediastinal involvement, an accepted unfavourable
prognostic factor (1), where evidence supports induction
chemotherapy (iCT) before surgery (2-5). Since resection
may sometimes be debatable or not indicated (large N2 or
N3 class), and since some patients (pts) may be unfit for
surgery for medical reasons, radiotherapy (RT) is often an
alternative treatment (6). To date, unconventional RT
schedules have been tested with encouraging results to
increase local control (7-9). As far as integrated treatments
are concerned, concomitant chemoradiation has been shown
to be an effective strategy (10-12); nevertheless, it has
resulted in higher toxicity (13-16). Thus, sequential
treatment has often been performed (17-20).
The long-term results of a prospective study investigating
three-times daily RT (3tdRT) after iCT in NSCLC with
histologically confirmed mediastinal involvement are reported.
Patients and Methods
The treatment and patient characteristics have been previously
described (21). Three cycles of cisplatin and gemcitabine, repeated
every 3 weeks, were scheduled in mediastinoscopy-based stage
IIIA(N2)-IIIB NSCLC pts, unless disease progression (PD) or
severe toxicity occurred. The response was evaluated after two
cycles (22). The resectable IIIA pts, without PD, underwent surgery
and postoperative (post-op) 3tdRT; the IIIB and unresectable IIIA
pts, underwent definitive 3tdRT. Metastatic pts were excluded from
the study. The 3tdRT doses were 54.4 Gy and 64.6 Gy for post-op
and definitive pts, respectively; the doses were delivered in three-
daily fractions of 1.2 Gy, 1 Gy and 1.2 Gy, with a minimal inter-
fraction interval of 5 hours, five days a week, according to the
Linear Quadratic Model (23). The "Concomitant Boost" technique
was used as follows. A "large" volume was irradiated via opposed
anterior-posterior fields, in the first and third daily fraction, up to
38.4 Gy. This volume consisted of the pre-iCT gross disease and
elective bilateral mediastinal irradiation, with a 1-2 cm safety
margin; for upper lobe tumors, the ipsilateral supraclavicular nodes
were treated. In the second daily fraction, a "boost" volume, limited
to the gross tumor volume (plus a 1.5 cm margin), was treated with
“off-cord” fields, up to an additional 16 Gy. In the definitive group,
after 54.4 Gy treatment was continued on “boost” volume only,
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three times a day, up to 64.6 Gy. The schedule followed the
International Committee of Radiation Units Report 50
recommendations (24).
Follow-up started four weeks after treatment and continued every
four months unless an unexpected clinical event occurred. RT acute
and late toxicities were scored according to Radiation Therapy
Oncology Group (RTOG) / European Organization for Research and
Treatment of Cancer (EORTC) System. The hospital Ethical
Committee approved the study and all the pts gave informed consent.
The primary study objective was to determine if an intensive
locoregional approach, with 3tdRT, combined with standard
treatment, should be investigated in a Phase II study. The primary
end-point was local progression; secondary end-points were PD (local
or distant) and overall survival (OS). The study was designed to
detect local PD, as the sole pattern of failure, of 20% compared with
a maximal, clinically unacceptable local progression of 45% ,
adopting the 3tdRT after iCT in NSCLC. A sample size of 37 pts
would achieve 90% power to detect a difference of 25% using a two-
sided binomial test. The target significance level was 0.05. Statistics
and frequency tables data are given whenever appropriate. Survival-
time was computed from the first iCT cycle to the date of event
occurrence; in event-free individuals, the observation-time was
recorded at the last follow-up. The OS curves were obtained with the
Kaplan-Meier method. The log-rank test was used to compare
survival between groups. Differences with a p-value ≤0.05 were
considered statistically significant. Statistical analyses were performed
with the SAS package, version 8.2 (SAS Institute, Cary, NC, USA).
Results
From February 1998 to October 2000, 52 pts (39 IIIA, 13
IIIB) were enrolled (Table I, Figure 1). Radical surgery was
performed in 25 pts (19 lobectomies, 5 pneumonectomies
and 1 segmentectomy). In 5 pts, surgical complications
occurred (1 adult respiratory distress syndrome, 4 heart
failure), all recovered. 3tdRT was performed in 19 of the
radically resected IIIA, 1 not radically resected IIIA, 5 non-
resected IIIA and 12 IIIB pts. Thus, 37 pts underwent 3tdRT
(18 definitive, 19 post-op). 3tdRT was not performed in 15
pts, due to progressive disease (10 pts), protocol violation (4
pts) and surgical morbidity (ARDS) in one patient. All but
one pt reached the planned dose (one post-op patient stopped
at 51 Gy). Acute 3tdRT toxicity was mainly esophagitis,
grade 2 (RTOG) in 25 pts (67.6% ) and grade 3 in 4 pts
(10.8% ) (21). All but seven pts died, two pts were lost to
follow-up after 8 and 28 months, respectively.
The failure patterns were evaluated for all 52 pts and in
the 3tdRT subgroup (37 pts). In the whole group, 42 PD
occurred (14 local, 25 systemic, 2 local + systemic, 1
unknown), seven pts were free of disease at last follow-up
(Table II). In the 37 irradiated pts, 29 PD occurred (8 local,
18 systemic, 2 both, 1 unknown). The failure patterns were
also stratified between post-op and definitive 3tdRT with no
difference between groups (78.9% vs. 77.8% , respectively).
In the post-op 3tdRT pts local failure occurred in 4 out of 19
irradiated pts (21% ), with higher incidence of distant
metastases (Table II). In the definitive 3tdRT group, the rate
of local and systemic PD were 33.3% and 44.4% ,
respectively. Brain failures were equal in the two groups:
3/12 in the post-op (25% of distant relapses) and 2/8 in the
definitive 3tdRT (25% of distant PD).
The median OS and 2-year and 5-year OS rates were 15
months, 40% and 19% , respectively (Table III). For stage
IIIA and IIIB, 2-year and 5-year OS were 44% and 19%
and 26% and 17% , respectively (Figure 2), without any
statistical difference (p=0.78 at 5 years). No differences were
demonstrated for surgery, response to iCT, pathological N2
stations or clinical stage (Table III, Figure 2).
In the 3tdRT pts, the 2-year and 5-year OS was 55% and
25% for the post-op pts vs. 42% and 21% for the definitive
pts, respectively (Table III, Figure 3).
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Table I. Patient and disease characteristics.
Characteristic Number of Percentage
patients
Age (years)





Median 90 (range 70-100)
Histology
Squamous cell 26 50%
Adenocarcinoma 19 36%
Other NSCLC 4 8%














Resected total lymph nodes*
Median 20 (range 5-40)
Resected mediastinal lymph nodes*
Median 12 (range 2-25)
Involved N2 stations*
Median 2 (range 0-4)
Involved N2 lymph nodes*
Median 3 (range 0-14)
†KPS, Karnofski performance status; *referred only to completely
resected stage IIIA patients (25).
Discussion
At the study planning, the present protocol represented, on
the basis of our knowledge, one of the first experiences of
platinum-based iCT with sequential 3tdRT in stage IIIA-B
NSCLC. Since surgical resection represented the preferred
local treatment, definitive 3tdRT was originally reserved only
for the unresectable IIIA and IIIB pts; afterwards, IIIA
resected pts were offered the most effective systemic option
(platinum-based CT) and the most effective local treatment
(post-op 3tdRT). As a consequence, this choice increased the
population heterogeneity, reducing the statistical power of
the study. Conscious of such a limitation, the results are
reported not only for the whole population, but also on the
basis of irradiation purpose (post-op and definitive 3tdRT).
Three main aspects emerged: satisfactory compliance with
therapy, a higher incidence of systemic failures over
locoregional progressions, especially in the resected pts, and
a similar long-term outcome for the definitive 3tdRT and
post-op irradiation treatments.
Compliance was much better than expected. Most of the
pts completed the planned iCT and only 8% of pts stopped
treatment before the last cycle, confirming the good regimen
tolerance (25-29). In contrast to the literature (30), only
18% of the resected pts experienced severe perioperative
morbidity, without any fatal event. A possible explanation
may be the low number of pneumonectomies performed,
since it has been reported that surgical extension is predictive
of complications after iCT (31). As far as radiation-induced
toxicity was concerned, all but one irradiated patient
completed the 3tdRT with only 10.8% of severe esophagitis,
well below reported data (8, 32). Although this finding could
possibly be attributable to incidental favourable patient
selection (21), the possible potential favourable impact of the
treatment strategy itself on the observed tolerance should not
be excluded, as similar findings of 10% of severe dysphagia
in the Continuous Hyperfractionated Accelerated Radiation
Therapy Week End Less (CHARTWEL) Trial have been
reported (33). A substantial number of pts (15 out of 52,
29% ) did not proceed to 3tdRT for various reasons,
introducing a potential lack of feasibility of the study.
Nevertheless, the discontinuations were mainly due to PD
(10 pts) at various stages of the treatment (iCT start - 3tdRT
end) and seemed mostly to reflect the natural history of the
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Figure 1. Flow chart of study design and treated patients. 3tdRT, Three-times daily radiotherapy; PD, disease progression.
disease rather than study compliance. Similar findings have
been reported elsewhere, such as in the Cancer And
Leukaemia Group B (CALGB) 8935 trial where, out of 74
enrolled pts, only 43 (58% ) completed the planned
scheduled treatment, due to overcoming PD, deaths or other
reasons (34).
Although the overall rate of failures was similar in the
post-op and definitive 3tdRT pts, the failure patterns
reflected the local treatment performed. As expected, surgery
by itself led to better local control, thus, in the post-op 3tdRT
pts a higher incidence of metastases than local recurrences
occurred (Table II). In constrast, in the definitive 3tdRT
group the failures were more balanced, with only a slight
prevalence of systemic spread over local PD. Kumar et al.
reported on a similar trend (34). Overall, 70% of pts failed,
but while the resected pts experienced predominantly distant
spread, in the unresectable pts local relapses were more
frequent. The metastases among the post-op pts might
therefore reflect either possible iCT ineffectiveness in
eradicating occult disease at the time of surgery, or the
ability of resection plus post-op RT to increase local control,
shifting the first failure to a distant site. In the unresectable
disease, it was concluded that the results represented an
indirect validation of the ability of non-surgical treatment to
control bulky locoregional disease (17, 34, 35). Although the
present findings did not differ consistently from the CALGB
trial especially for the resected pts, the possible inadequacy
of iCT in preventing metastatic spread from occult disease
was unlikely, since the regimen has proved its effectiveness
(25, 26, 28, 29); furthermore, the planned number of cycles
is a common standard and evidence does not exist supporting
a prolongation for more than three cycles. Positron
tomography (PET) was not included in the planned staging
as a routine procedure in the present study. Since the role of
PET in the early diagnosis of NSCLC metastases is now
established (36-38), it is likely that a consistent number of
ANTICANCER RESEARCH 28: 4121-4128 (2008)
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Table II. Patterns of progression for the whole population and stratified for treatment.
Total patients 3tdRT patients IIIA Post-op IIIA-B Definitive
(n=52) (n=37) 3tdRT patients 3tdRT patients
(n=19) (n=18)
Disease-free at last follow-up 7 (13.5% ) 6 (16.2% ) 3 (15.8% ) 3 (16.7% )
PD 42 (80.7% ) 29 (78.4% ) 15 (78.9% ) 14 (77.8% )
Local 14 (26.9% ) 8 (21.6% ) 2 (10.5% ) 6 (33.3% )
Systemic 25 (48.1% ) 18 (48.6% ) 10 (52.6% ) 8 (44.4% )
Both 2 (3.8% ) 2 (5.4% ) 2 (10.5% ) -
Unknown 1 (1.9% ) 1 (2.7% ) 1 (5.3% ) -
Unknown 3 (5.8% ) 2 (5.4% ) 1 (5.3% ) 1 (5.5% )
3tdRT, three-times daily radiotherapy; Post-op, postoperative; PD, disease progression.
Table III. Survival for the whole population and stratified for treatment.
Median OS 2-Year OS 5-Year OS p-Value
(months)
Total population (52 pts.) 15 40% 19% -
Clinical stage (IIIA vs. IIIB) 19 vs. 13 44% vs. 26% 19% vs. 17% 0.78
Response to iCT (PR vs. SD) 46% vs. 25% 17% vs. 25% 0.32
Surgery vs. no surgery 45% vs. 33% 20% vs. 16% 0.50
IIIA after surgery (28 pts.)
Radical vs. non-radical surgery 52% vs. 0% 23% vs. 0% 0.04
IIIA after radical surgery (25 pts.)
N2 positive stations (≤2 vs. >2) 69% vs. 22% 31% vs. 11% 0.13
3tdRT patients (37 pts.)
Postoperative vs. definitive 3tdRT 27 vs. 15 55% vs. 42% 25% vs. 21% 0.87
OS, Overall survival; iCT; induction chemotherapy; PR, partial response; SD, stable disease; 3tdRT, three-times daily radiotherapy.
pts already had occult systemic disease at diagnosis, thus
affecting the results, especially in the post-op pts, where
local control was more likely to be achieved with resection.
Compared with others (17, 34, 39), a prevalence of local
over systemic failures was not observed in the definitive 3tdRT
pts, on the contrary, local PD did not outweigh metastases.
Although the low number of pts did not allow definitive
conclusions, slight 3tdRT effectiveness in local disease control
might be hypothesized. As pointed out, the three pts actually
alive in this group reached a complete response after
irradiation and were still free of disease at the last follow-up.
Within the statistical limitations it could be speculated that in
a restricted group of stage III pts, when disease is still loco-
regional, a more intensive local treatment might improve
disease control and consequently outcome. The impact of local
control on survival, has already been demonstrated in the
study of Rojas et al. where 2-year OS was significantly
affected by the achievement of primary tumor control (33).
As far OS was concerned, the present findings were
comparable to other series (34). Although a short-term OS
difference occurred between stage IIIA and IIIB, it was lost at
longer follow-up. Similar results occurred in the restricted group
of irradiated pts, where the 2-year difference between post-op
and definitive 3tdRT pts was no longer observed after 5 years.
Despite the lack of statistical significance, due to the low
statistical power, a better outcome for definitive 3tdRT may be
argued; on the other hand, it is also possible that this observation
could be consequent on the sub-optimal result for the post-op
pts. Both explanations are reasonable. Lorent et al. in a
trimodality protocol for IIIA-N2 pts, reported a 5-year OS of
21% for the whole population, although post-op pts
experienced a 5-year OS of 35% , slightly better than the present
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Figure 2. Overall survival relative to surgery (A), response to induction chemotherapy (PD, disease progression; PR, partial response; SD, stable
disease) (B), clinical stage (stage IIIA, stage IIIB) (C), and number of positive mediastinal lymph nodal stations at surgery (0-2, more than 2) (D).
25% (40). Belani et al. reported on stage IIIA-B pts treated
sequentially with iCT and definitive 3tdRT, observing a 2-year
OS of 44% comparable to the present 42% (41). Finally,
Hishikura et al. in a similar study for stage III pts, experienced
a 2-year OS of 50% , but local failure was high (57% )
compared to metastases (30% ) and the authors underlined the
importance of further local control improvement (42).
Conclusion
The reported treatment is feasible and well tolerated with
good compliance and low toxicity. No significant outcome
improvement of 3tdRT as post-op treatment occurred in stage
IIIA pts, where local control was managed by surgery. 3tdRT
as definitive treatment may have a role in selected pts; the
potential candidates represent a very restricted group in
which the disease, although locally advanced, is still
locoregional, thus justifying a more intensive local approach.
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